scholarly journals Efficacy of Adapalene 0.1% Versus Tretinoin 0.025% Cream as Treatment of Mild Acne Vulgaris

2020 ◽  
Vol 4 (2) ◽  
pp. 18-25
Author(s):  
Sarah Diba ◽  
Zahra Ayu Lukita Sari ◽  
Muhammad Athuf Thaha
Keyword(s):  
Acne Vulgaris ◽  
Inflammatory Lesion ◽  
Inclusion Criteria ◽  
First Line ◽  
Pilosebaceous Unit ◽  
Double Blind ◽  
Inflammatory Lesions ◽  
Topical Retinoid ◽  
Double Blind Clinical Trial ◽  
First Line Treatment

Abstract   Introduction: Acne vulgaris (AV) is a chronic inflammatory of the pilosebaceous unit. Topical retinoid is a mainstay of mild AV first-line treatment. Aim of study: To assess the efficacy of topical retinoid for the treatment of mild AV. Method: The randomized double-blind clinical trial was conducted from June to September 2019 at Dr. Mohammad Hoesin General Hospital Palembang. A total of 70 mild AV patients who fulfilled inclusion criteria were enroled consecutively. Patients randomly treated with adapalene 0.1% cream or tretinoin 0.025% cream and evaluated every 2 weeks for 8 weeks to examine the number of AV lesion (inflammation, non-inflammation and total lesion). Result: There are reduction in number of inflammatory and non-inflammatory lesions at both groups but only inflammatory lesion was statistically significant (p <0.05). Total lesions also decrease in adapalene and retinoin group (21.66 vs 5.75, 22.21 vs 7.96, respectively) and statistically significant (p <0.05). Conclusion: Adapalen 0.1% cream showed non-inferiority to tretinoin 0.025% cream in efficacy, especially in the reduction of non-inflammatory and total lesions.

scholarly journals The Effect of Intravenous Lidocaine on Trigeminal Neuralgia: A Randomized Double Blind Placebo Controlled Trial

ISRN Pain ◽  
2014 ◽  
Vol 2014 ◽  
pp. 1-5 ◽  
Author(s):  
Evmorfia Stavropoulou ◽  
Erifili Argyra ◽  
Panagiotis Zis ◽  
Athina Vadalouca ◽  
Ioanna Siafaka
Keyword(s):  
Trigeminal Neuralgia ◽  
Controlled Trial ◽  
Line Treatment ◽  
Intravenous Lidocaine ◽  
Inclusion Criteria ◽  
First Line ◽  
Double Blind ◽  
Double Blind Placebo ◽  
Therapeutic Results ◽  
First Line Treatment

Trigeminal neuralgia is the most common neuralgia. Its therapeutic approach is challenging as the first line treatment often does not help, or even causes intolerable side effects. The aim of our randomized double blind, placebo controlled, crossover study was to investigate in a prospective way the effect of lidocaine in patients with trigeminal neuralgia. Twenty patients met our inclusion criteria and completed the study. Each patient underwent four weekly sessions, two of which were with lidocaine (5 mgs/kg) and two with placebo infusions administered over 60 minutes. Intravenous lidocaine was superior regarding the reduction of the intensity of pain, the allodynia, and the hyperalgesia compared to placebo. Moreover, contrary to placebo, lidocaine managed to maintain its therapeutic results for the first 24 hours after intravenous infusion. Although, intravenous lidocaine is not a first line treatment, when first line medications fail to help, pain specialists may try it as an add-on treatment. This trial is registered with NCT01955967.

scholarly journals Efficacy of Dapsone 5% gel in treatment of Acne vulgaris

2016 ◽  
Vol 2 (4) ◽  
pp. 77
Author(s):  
Sugat A. Jawade ◽  
Adarshlata Singh
Keyword(s):  
Success Rate ◽  
Acne Vulgaris ◽  
Inflammatory Disorder ◽  
Inclusion Criteria ◽  
Pilosebaceous Unit ◽  
Open Label ◽  
Inflammatory Lesions ◽  
Chronic Inflammatory Disorder ◽  
Medical College ◽  
Jawaharlal Nehru

<p class="abstract"><strong>Background:</strong> Acne vulgaris is chronic inflammatory disorder of pilosebaceous unit mainly characterized by comedones, papules and nodulocystic lesions affecting face and upper trunk. Topical dapsone 5% gel is approved to treat acne vulgaris because of its anti-inflammatory and anti-bacterial activities.</p><p class="abstract"><strong>Methods:</strong> A single center, open label interventional study was conducted during 1 year period in dermatology OPD of Jawaharlal Nehru Medical College, Sawangi (Meghe), Wardha, Maharashtra. Patients were enrolled in the study considering inclusion criteria. Patients were asked to apply dapsone 5% gel twice daily on face for 12 week. Efficacy was evaluated by mean percent reduction in total, inflammatory and non-inflammatory lesions and success rate on change in investigator global acne severity assessment scale while tolerability was assessed by evaluating skin dryness, erythema, stinging or burning sensation and scaling at baseline, 1, 2, 4, 8 and 12 week.<strong></strong></p><p class="abstract"><strong>Results:</strong> At end of 12 week, success rate reached to 31.54%. Dapsone 5% gel was effective in reduction of total, non-inflammatory and inflammatory lesions by 57.75%, 52% and 63.1% respectively. Side effects with dapsone gel were tolerable, mild and transient.</p><p><strong>Conclusions:</strong> Dapsone 5% gel was efficacious and well tolerated in non-inflammatory as well as inflammatory acne lesions. </p>

Sidharthakadi Lepa in Mukhadushika - A Clinical Study

2018 ◽  
Vol 3 (01) ◽  
Author(s):  
Ravindra Angadi ◽  
Rekha J.
Keyword(s):  
Skin Disorder ◽  
Acne Vulgaris ◽  
Response To Therapy ◽  
Inclusion Criteria ◽  
Pilosebaceous Unit ◽  
External Application ◽  
Acne Lesion ◽  
Common Skin ◽  
The Face ◽  
Inflammatory Component

Background: Acne vulgaris is a very common malady of adolescents. It is common enough to be called as a physiological process but is better regarded as a disease due to its inflammatory component and the disfigurement. Acne vulgaris is a common skin disorder of pilosebaceous unit that primarily affects the face which if not treated leads to pigmentation. Mukhadushika is a Kshudra Roga which mainly involves Kapha and Vatadosa with Raktha. This is a common illness affecting 80 % of adolescents. Lepa is one of the external therapies explained in Ayurvedic classics. Objectives: To evaluate the efficacy of Sidharthakadilepa in the management of mukhadushikaw.s.r. to acne vulgaris. Methods: 30 patients fulfilling the inclusion criteria were selected. They were given Sidharthakadi Lepa for external application over face for one month. Patients were observed for changes on 7th, 14th, 21st and 28th day. The response to therapy was evaluated at the end of 28 days by calculating acne lesion score and the efficacy was determined by the percentage reduction in ALS. Results: The analysis revealed that 40% of patients had complete remission, 30% patients showed marked improvement and 30% showed moderate improvement.

scholarly journals Efficacy and Safety of Azelaic Acid Nanocrystal-Loaded In Situ Hydrogel in the Treatment of Acne Vulgaris

Pharmaceutics ◽  
2021 ◽  
Vol 13 (4) ◽  
pp. 567
Author(s):  
Ivona Tomić ◽  
Sandra Miočić ◽  
Ivan Pepić ◽  
Dubravka Šimić ◽  
Jelena Filipović-Grčić
Keyword(s):  
Azelaic Acid ◽  
Controlled Trial ◽  
Acne Vulgaris ◽  
Topical Therapy ◽  
Adverse Event Rate ◽  
Double Blind ◽  
Inflammatory Lesions ◽  
First Choice ◽  
In Situ Hydrogel

Acne vulgaris is a common, multifactorial, inflammatory skin disease affecting the pilosebaceous unit. Topical therapy is the first choice in the treatment of mild to moderate acne, and azelaic acid (AZA) is one of the most commonly used drugs. The aim of this study was to evaluate the safety and efficacy of a low-dose azelaic acid nanocrystal (AZA-NC) hydrogel in the treatment of mild to moderate facial acne. The study was designed as a double-blind, randomized controlled trial. Patients were randomized to treatment with AZA-NC hydrogel, 10%, or AZA cream, 20%, administered in quantities of approximately 1 g twice daily for 8 weeks. Efficacy of therapy was measured by the number of lesions and safety by the frequency and severity of adverse events. At week 8, the success rate of treatment with AZA-NC hydrogel, 10%, was 36.51% (p < 0.001) versus 30.37% (p < 0.001) with AZA cream. At week 8, treatment with AZA-NC hydrogel, 10%, resulted in a significant reduction in total inflammatory lesions from baseline of 39.15% (p < 0.001) versus 33.76% (p < 0.001) with AZA cream, and a reduction in non-inflammatory lesions from baseline of 34.58% (p < 0.001) versus 27.96% (p < 0.001) with AZA cream, respectively. The adverse event rate was low and mostly mild.

scholarly journals Prospective Parallel Randomized, Double-Blind, Double-Dummy Controlled Clinical Trial Comparing Clomiphene Citrate and Metformin as the First-Line Treatment for Ovulation Induction in Nonobese Anovulatory Women with Polycystic Ovary Syndrome

2005 ◽  
Vol 90 (7) ◽  
pp. 4068-4074 ◽  
Author(s):  
Stefano Palomba ◽  
Francesco Orio ◽  
Angela Falbo ◽  
Francesco Manguso ◽  
Tiziana Russo ◽  
...  
Keyword(s):  
Polycystic Ovary ◽  
Clomiphene Citrate ◽  
Controlled Clinical Trial ◽  
Line Treatment ◽  
First Line ◽  
Ovary Syndrome ◽  
Double Blind ◽  
Group A ◽  
Group B ◽  
First Line Treatment

Abstract Context: Although metformin has been shown to be effective in the treatment of anovulation in women with polycystic ovary syndrome (PCOS), clomiphene citrate (CC) is still considered to be the first-line drug to induce ovulation in these patients. Objective: The goal of this study was to compare the effectiveness of metformin and CC administration as a first-line treatment in anovulatory women with PCOS. Design: We describe a prospective parallel randomized, double-blind, double-dummy controlled clinical trial. Setting: The study was conducted at the University “Magna Graecia” of Catanzaro, Catanzaro, Italy. Patients: One hundred nonobese primary infertile anovulatory women with PCOS participated. Interventions: We administered metformin cloridrate (850 mg twice daily) plus placebo (group A) or placebo plus CC (150 mg for 5 d from the third day of a progesterone withdrawal bleeding) (group B) for 6 months each. Mean outcome measures: The main outcome measures were ovulation, pregnancy, abortion, and live-birth rates. Results: The subjects of groups A (n = 45) and B (n = 47) were studied for a total of 205 and 221 cycles, respectively. The ovulation rate was not statistically different between either treatment group (62.9 vs. 67.0%, P = 0.38), whereas the pregnancy rate was significantly higher in group A than group B (15.1 vs. 7.2%, P = 0.009). The difference found between groups A and B regarding the abortion rate was significant (9.7 vs. 37.5%, P = 0.045), whereas a positive trend was observed for the live-birth rate (83.9 vs. 56.3%, P = 0.07). The cumulative pregnancy rate was significantly higher in group A than group B (68.9 vs. 34.0%, P &lt; 0.001). Conclusions: Six-month metformin administration is significantly more effective than six-cycle CC treatment in improving fertility in anovulatory nonobese PCOS women.

Sign in / Sign up

Export Citation Format

Share Document